New model predicts drug-target affinity effectively, using evolutionary data and multi-scale graphs, enhancing discovery.
Drug-target affinity (DTA) prediction is crucial for drug discovery. While protein evolutionary features are vital for identifying conserved regions, current methods rely on computationally expensive multiple sequence alignment (MSA), creating a significant bottleneck. To address this, we propose MAFI-DTA, a novel model that circumvents the computational burden of MSA by deriving evolutionary context directly from sequences using the advanced protein language model, ESM-3. Furthermore, we introduced a multi-scale protein graph construction strategy based on varying numbers of residues, enabling the effective extraction of structural information across different scales through a neural network integrating graph neural networks, BiLSTM, and transformer modules. Experimental validation on multiple benchmark datasets demonstrates that MAFI-DTA achieves significantly better performance compared to existing approaches. This improved accuracy is attributed to the effective incorporation of both the predicted evolutionary information and the multi-scale graph representations. The source code is available at https://github.com/aliveadult/MAFI. MAFI-DTA successfully captures crucial evolutionary and multi-scale structural context efficiently, overcoming the limitations of traditional MSA methods. This approach provides a high-performing tool that facilitates the study of drug–target interactions and accelerates the drug discovery process.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: